六氢-环戊并[c]吡咯-4(1h)-酮(9ci) | 732956-04-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 六氢-环戊并[c]吡咯-4(1h)-酮(9ci)
• 中文别名: 六氢环戊烷并[C]吡咯-4(2H)-酮
• 英文名称: 6-Oxo-3-azabicyclo[3.3.0]octane
• 英文别名: (1R*, 5S*)-6-Oxo-3-azabicyclo[3,3,0]octane；Hexahydrocyclopenta[c]pyrrol-4(2H)-one；2,3,3a,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-4-one
• CAS: 732956-04-6
• 化学式: C₇H₁₁NO
• mdl: MFCD09997899
• 分子量: 125.17
• InChiKey: VTJCOTZQTGPOSP-UHFFFAOYSA-N

物化性质

• 沸点：
  223.3±13.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  六氢-环戊并[c]吡咯-4(1h)-酮(9ci) 在 氢气 作用下， 200.0 ℃ 、3.0 MPa 条件下， 以92 %的产率得到八氢环戊烷[C]吡咯
  参考文献：
  名称：

  CN115160210

  摘要：

  公开号：

文献信息

• [EN] COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS<br/>[FR] COMPOSÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013027001A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6, X1, X2, X3, X4, A1 and L1, are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（1）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、m、n、p、q、Q1、Q2、Q3、Q4、Q5、Q6、X1、X2、X3、X4、A1和L1如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Azabicycloalkanes
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0359172A1

  公开（公告）日：1990-03-21

  Azabicycloalkanes of the general formula: wherein R¹ and R² each is hydrogen, hydroxy, oxo, halogen, azido, amino, C₁-C₃ alkylamino, or aminomethyl, in which said amino, C₁-­C₃ alkylamino and aminomethyl each is optionally substituted by one or two members selected from the group consisting of C₁-C₃ alkyl and amino-protecting group; n is an integer of 1 to 3; p and q each is an integer of 0 to 3 with proviso that p+q=1 to 4 or acid-addition salts thereof, being useful materials for preparing side chains of antibacterial quinolonecarboxylic acids, cephalos­porines, or other antibiotics.

  通式如下的氮杂双环烷烃 其中 R¹ 和 R² 各为氢、羟基、氧代、卤素、叠氮、氨基、C₁-C₃ 烷基氨基或氨基甲基，其中所述氨基、C₁-C₃ 烷基氨基和氨基甲基可任选被选自 C₁-C₃ 烷基和氨基保护基团的一个或两个成员取代；n 为 1 至 3 的整数；p 和 q 分别为 0 至 3 的整数，但 p+q=1 至 4 或其酸加成盐，是制备抗菌喹啉羧酸、头孢菌素或其他抗生素侧链的有用材料。
• Discovery of (<i>R</i>)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu₃ Selective and CNS Penetrant Negative Allosteric Modulator (NAM)
  作者：Cody J. Wenthur、Ryan Morrison、Andrew S. Felts、Katrina A. Smith、Julie L. Engers、Frank W. Byers、J. Scott Daniels、Kyle A. Emmitte、P. Jeffrey Conn、Craig W. Lindsley

  DOI：10.1021/jm400439t

  日期：2013.6.27

  A multidimensional, iterative parallel synthesis effort identified a series of highly selective mGlu(3) NAMs with submicromolar potency and good CNS penetration. Of these, ML337 resulted (mGlu(3) IC50 = 593 nM, mGlu(2) IC50 >30 mu M) with B:P ratios of 0.92 (mouse) to 0.3 (rat). DMPK profiling and shallow SAR led to the incorporation of deuterium atoms to address a metabolic soft spot, which subsequently lowered both in vitro and in vivo clearance by >50%.
• QUINOLIZINONE TYPE COMPOUNDS
  申请人：ABBOTT LABORATORIES

  公开号：EP0723545B1

  公开（公告）日：2002-05-08